Daxxify (daxibotulinumtoxinA-lanm) / Fosun Pharma, Crown Labs - LARVOL DELTA

The Role of Toxins and Fillers in Optimizing Perioral Rejuvenation. (PubMed, Facial Plast Surg) - "Changes in the perioral region are significant contributors to the visible signs of aging.Ideal candidates for perioral rejuvenation with toxin and filler are individuals experiencing age-related rhytids or volume loss who are interested in minimally invasive, nonsurgical interventions.Neurotoxins like Botox, Xeomin, Dysport, Jeuveau, and Daxxify are used to relax muscles that contribute to rhytids...Dermal fillers such as hyaluronic acid, calcium hydroxyapatite, and poly-L-lactic acid restore volume in areas like the nasolabial folds, lips, marionette lines, chin, prejowl sulcus, and perioral rhytids.Neurotoxins and dermal fillers offer effective, minimally invasive solutions for perioral rejuvenation. With an understanding of underlying anatomy, proper patient selection, and precise injection techniques, facial plastic surgeons can achieve natural, youthful results with minimal downtime."

Journal • Aesthetic Medicine

Long-Term Safety and Efficacy of Repeat Treatments with DaxibotulinumtoxinA in Cervical Dystonia: Results from the ASPEN-Open-Label Study. (PubMed, Mov Disord Clin Pract) - P3 | "DAXI was safe and efficacious over repeated treatments in adults with CD. Adverse event rates were similar to or potentially lower compared with conventional BoNTs."

Journal • CNS Disorders • Dystonia • Gastrointestinal Disorder • Movement Disorders • Pain

Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy (clinicaltrials.gov) - P2 | N=4 | Terminated | Sponsor: OHSU Knight Cancer Institute | N=63 ➔ 4 | Trial completion date: May 2025 ➔ Jul 2024 | Recruiting ➔ Terminated | Trial primary completion date: May 2025 ➔ Jul 2024; low enrollment

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Oncology • Solid Tumor

Exploring Nonresponse to Botulinum Toxin in Aesthetics: Narrative Review of Key Trigger Factors and Effective Management Strategies. (PubMed, JMIR Dermatol) - "Neutralizing antibodies developed with first-generation formulations, such as onabotulinumtoxinA and abobotulinumtoxinA that contain clostridial proteins, but not with second-generation BoNT-As, such as incobotulinumtoxinA and daxibotulinumtoxinA, which lack these proteins...Considering the potential for immunogenicity is essential when selecting a BoNT-A formulation. Preventing SNR is crucial, given the lack of solid data on effective treatments."

Journal • Review • Aesthetic Medicine • Infectious Disease

A Prospective Clinical Trial Comparing Daxibotulinumtoxina-Ianm (DAXI) to Onabotulinumtoxina (BTXA) for Adductor Type Laryngeal Dystonia (ADLD) (COSM 2025) - "Daxi was found to be safe and effective, with 37% of patients reporting longer duration of voice benefit than with BtxA. Mean duration of voice benefit was 47% longer than previous BtxA treatments."

Clinical • CNS Disorders • Dystonia • Movement Disorders

Safety and Efficacy of Repeat Administration and Dose Escalation of DaxibotulinumtoxinA-lanm (Daxi) Versus OnabotulinumtoxinA (BtxA) for Adductor Type Laryngeal Dystonia (AdLD) (COSM 2025) - No abstract available

Clinical • CNS Disorders • Dystonia • Movement Disorders

Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines (clinicaltrials.gov) - P2 | N=27 | Completed | Sponsor: Revance Therapeutics, Inc. | Recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Feb 2025 | Trial primary completion date: May 2025 ➔ Dec 2024

Trial completion • Trial completion date • Trial primary completion date

Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm (clinicaltrials.gov) - P4 | N=40 | Recruiting | Sponsor: Montefiore Medical Center | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders

Efficacy Remaining at Time of Requested Re-Treatment for Cervical Dystonia: A Potential New Treatment Paradigm with DaxibotulinumtoxinA. (PubMed, Toxins (Basel)) - "A significant proportion of CD patients wished to be re-treated with efficacy still remaining from prior BoNT injections as early symptoms re-emerged. With the overall clinical profile of DAXI, physicians can safely provide individualized treatment regimens based on the treatment goals or symptomatic needs of their patients."

Clinical • Journal • CNS Disorders • Dystonia • Gastrointestinal Disorder • Movement Disorders

DaxibotulinimtoxinA for Treatment of Platysmal Neck Bands (clinicaltrials.gov) - P4 | N=20 | Completed | Sponsor: Main Line Center for Laser Surgery | Recruiting ➔ Completed | Trial completion date: Jan 2026 ➔ Jan 2025

Trial completion • Trial completion date

DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia (clinicaltrials.gov) - P1/2 | N=22 | Completed | Sponsor: University of California, San Francisco | Active, not recruiting ➔ Completed | Trial completion date: Jun 2025 ➔ Mar 2025 | Trial primary completion date: Jun 2025 ➔ Mar 2025

Trial completion • Trial completion date • Trial primary completion date • Dysphonia • Otorhinolaryngology

Successful Treatment of Sialorrhea with Daxibotulinum Toxin A (AAN 2025) - "Currently, IncobotulinumtoxinA (USA and Europe) and RimabotulinumtoxinB (USA) are approved for this indication. All surveys suggest DaxibotulinumtoxinA provided sustained improvement of sialorrhea and may provide a novel alternative option for those refractory to other treatments."

CNS Disorders • Movement Disorders • Parkinson's Disease

Insights from Clinical Experience with DaxibotulinumtoxinA for the Treatment of Cervical Dystonia (AAN 2025) - "Our cohort consisted of both toxin-naïve and toxin-experienced individuals allowing for a broad evaluation of dosing strategies and treatment outcomes.Patients received doses ranging between 60-570U, with toxin-experienced individuals transitioning from OnabotulinumtoxinA or IncobotulinumtoxinA using a conversion ratio ranging from 1:1 to 1:3. Daxxify is a good treatment option in patients with CD, particularly in patients unsatisfied with the outcomes of previous therapies. Further studies may be warranted to explore its broader applications in the treatment of other conditions and to optimize dosing strategies for individualized patient care."

Clinical • CNS Disorders • Dystonia • Gastrointestinal Disorder • Infectious Disease • Migraine • Movement Disorders • Pain • Parkinson's Disease

DaxibotulinumtoxinA Treatment for Laryngeal Respiratory Dystonia. (PubMed, J Voice) - "DAXI appears to provide ~80% better duration than the patient's average BtxA injection and a 57% improvement than his best BtxA injection. DAXI is a safe and realistic alternative to BtxA injection in patients with LRD."

Journal • CNS Disorders • Dystonia • Movement Disorders • Pulmonary Disease

Successful Treatment of Severe, Poorly Controlled Benign Essential Blepharospasm with DaxibotulinumtoxinA. (PubMed, Ophthalmic Plast Reconstr Surg) - "This case highlights a 57-year-old male with severe, poorly controlled benign essential blepharospasm despite high-dose injections of onabotulinumtoxinA and incobotulinumtoxinA...Notably, the patient experienced 50% to 75% efficacy retention at 3 months postinjection, significantly better than his response to other botulinum toxin type A products. This case suggests that daxibotulinumtoxinA may be an effective treatment for benign essential blepharospasm including patients experiencing poor symptom control with other botulinum toxin type A products."

Journal • CNS Disorders • Dystonia • Movement Disorders

Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information. (PubMed, Toxins (Basel)) - "Current clinical trials suggest that DAXI, a novel BoNTA formulation, provides a potentially wider safety margin compared with other approved BoNTAs for CD. The lower amount of core neurotoxin administered at approved doses compared with conventional BoNTAs may explain low on-target ADRs like muscle weakness, whereas reduced diffusion from the injection site is thought to be responsible for low off-target ADRs like dysphagia."

Journal • CNS Disorders • Dystonia • Gastrointestinal Disorder • Movement Disorders

Do Lower Doses of Botulinum Neurotoxin Type-A Offer a Longer Duration of Effect and Superior Efficacy in Patients with Cervical Dystonia? (MDS Congress 2024) - "Background: Recently, a long-acting neurotoxin, daxibotulinumtoxinA, was approved for cervical dystonia (CD)...Patients with a history of essential tremor, who previously received rimabotulinumtoxinB, or received injections for multiple indications, were excluded from the study. The cutoff between low-dose and high-dose groups was 220 units for those who received either onabotulinumtoxinA or incobotulinumtoxinA and 500 units for those who received abobotulinumtoxinA... Our preliminary data showed that patients administered a lower dose of BoNT-A reported a longer duration of effect and superior efficacy compared to those who received a higher dose. While a potential explanation for our result is a greater disease burden in patients requiring higher doses, it is also possible that there is a ceiling effect, and we are unnecessarily overdosing patients."

Clinical • CNS Disorders • Dystonia • Essential Tremor

DaxibotulinumtoxinA for injection to treat moderate or severe glabellar lines: A randomized, multicenter, Phase III, double-blind, placebo-controlled trial in China. (PubMed, J Plast Reconstr Aesthet Surg) - "DAXI provided durable efficacy and acceptable safety for treating moderate/severe glabellar lines in Chinese participants."

Journal • P3 data

A randomized, double-blind, placebo-controlled trial of DaxibotulinumtoxinA for Injection for the treatment of upper limb spasticity in adults after stroke or traumatic brain injury. (PubMed, PM R) - "Results from this Phase 2 study indicate that DAXI 500 U is effective and well tolerated for treatment of adults with ULS."

Clinical • Journal • Cardiovascular • CNS Disorders • Movement Disorders • Vascular Neurology

Efficacy Remaining at Time of Requested Retreatment Following Botulinum Toxin Treatment for Cervical Dystonia: Potential for a New Treatment Paradigm with DaxibotulinumtoxinA (MDS Congress 2024) - "These findings demonstrate, for the first time, a significant proportion of efficacy remained in patients who requested BoNT reinjection for their CD symptoms. With the long duration of benefit of daxibotulinumtoxinA, there is opportunity for a new approach whereby physicians can tailor treatments to individual patient needs and treat patients as their symptoms re-emerge at 12 weeks or beyond. This abstract has been accepted for presentation at AAN 2024 this April 13-18, 2024."

Clinical • CNS Disorders • Dystonia

Efficacy and Safety of DaxibotulinumtoxinA-lanm for Injection in Adults with Cervical Dystonia: Pooled Global Analysis of ASPEN-1 and ASPEN-1-CN (MDS Congress 2024) - "This pooled analysis of Phase 3 trials from the USA/EU (ASPEN-1) and China (ASPEN-1-CN) demonstrates that DAXI is an effective, safe, and long-acting treatment for CD. Key adverse events occurred at rates lower than prior pivotal trials of BoNT products for this indication."

Clinical • CNS Disorders • Dystonia

DAXXIFY® for Cervical Dystonia: From Clinical Trials to Real World Experience (MDS Congress 2024) - "Sponsored by Revance Therapeutics"

Clinical • Real-world • Real-world evidence • CNS Disorders • Dystonia

DAXXIFYTM (DaxibotulinumtoxinA-Lanm) for Injection, for Intramuscular Use. (PubMed, Skinmed) - "Treatment success proportions were 73.2%, 77.7%, and 79.6% across the three consecutive treatment cycles. The recommended dose is 40 units for the Glabellar-complex divided in traditional five intramuscular injections at five injection sites (medial and lateral corrugator bilaterally and one injection in the procerus muscle)."

Clinical • Journal

Clinical Benefits of DaxibotulinumtoxinA for Injection: Beyond Glabellar Line Effacement? (PubMed, Dermatol Surg) - "Advances in BoNTA technology can provide patients with greater options for treatment outcomes. The potential for enhanced localized effects with DAXI may contribute to more precise and targeted effects on muscle activity and additional aesthetic benefits to patients."

Journal • Review

Open Label, 6-month Study for High Frequency and Chronic Migraine, (clinicaltrials.gov) - P=N/A | N=20 | Active, not recruiting | Sponsor: Ki Health Partners. LLC | Recruiting ➔ Active, not recruiting | N=10 ➔ 20

Enrollment change • Enrollment closed • CNS Disorders • Migraine • Pain